# Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma

> **NCT05705791** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** QuiremSpheres

## Key facts

- **NCT ID:** NCT05705791
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-07
- **Primary completion:** 2026-02
- **Final completion:** 2026-08
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705791, "Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05705791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*